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Abstract
Background: The microenvironment and stress factors like glucocorticoids have a strong influence on breast
cancer progression but their role in the first stages of breast cancer and, particularly, in myoepithelial cell regulation
remains unclear. Consequently, we investigated the role of glucocorticoids in ductal carcinoma in situ (DCIS) in
breast cancer, focusing specially on myoepithelial cells.
Methods: To clarify the role of glucocorticoids at breast cancer onset, we evaluated the effects of cortisol and
corticosterone on epithelial and myoepithelial cells using 2D and 3D in vitro and in vivo approaches and human
samples.
Results: Glucocorticoids induce a reduction in laminin levels and favour the disruption of the basement membrane by
promotion of myoepithelial cell apoptosis in vitro. In an in vivo stress murine model, increased corticosterone levels
fostered the transition from DCIS to invasive ductal carcinoma (IDC) via myoepithelial cell apoptosis and disappearance
of the basement membrane. RU486 is able to partially block the effects of cortisol in vitro and in vivo. We found that
myoepithelial cell apoptosis is more frequent in patients with DCIS+IDC than in patients with DCIS.
Conclusions: Our findings show that physiological stress, through increased glucocorticoid blood levels, promotes the
transition from DCIS to IDC, particularly by inducing myoepithelial cell apoptosis. Since this would be a prerequisite for
invasive features in patients with DCIS breast cancer, its clinical management could help to prevent breast cancer
progression to IDC.
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Background
Breast cancer, the most frequent tumour among women
worldwide, is a heterogeneous disease [1]. The most com-
mon non-invasive breast cancer lesion is ductal carcinoma
in situ (DCIS) [2], defined as intraductal, since there is
clonal proliferation of cancerous epithelial cells within the
ductal lumen without spreading into the mammary
stroma and with the myoepithelial cell layer and basement
membrane (BM) remaining intact [2]. However, DCIS is
considered a non-obligatory precursor lesion of invasive
ductal carcinoma (IDC), in which the disappearance of
myoepithelial cells and the BM leads to the invasion of the
mammary stroma by tumour epithelial cells [3]. DCIS is a
highly heterogeneous lesion and the evolution differs in
each patient: some rapidly progress to IDC if untreated or
undertreated, whereas others remain virtually unaltered
for 5–20 years or never progress [4]. Epidemiologically,
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DCIS accounts for 15–25% of newly diagnosed breast can-
cer cases in the USA and this incidence is increasing [5],
while the frequency of IDC remains stable [6], indicating
that some DCIS will be over treated without therapeutic
benefit. Therefore, there is a need to improve the manage-
ment of patients with DCIS by matching the risk to each
individual, avoiding over/under treatment of patients with
DCIS to prevent the transition to IDC, which is less thera-
peutically affordable than DCIS.
Recent efforts have focused on unravelling the role of
cancerous epithelial cells in DCIS and IDC [4, 7]. How-
ever, the mechanisms regulating the transition from
DCIS to invasive carcinoma remain largely unknown,
hampering correct subsequent surgery and treatment.
The characteristic feature in the transition from DCIS to
IDC is the disappearance of the myoepithelial cell layer
and its BM [8], which is closely related to the loss of
function of myoepithelial cells, since the gene expression
of the main component of the BM, laminin, is altered
[9]. Myoepithelial cells play a crucial role as tumour sup-
pressors of the transition to the invasiveness of DCIS
[10]. However, despite recent progress in cell research
[11–13], the molecular mechanisms that regulate myoe-
pithelial cell layer disruption in the transition from DCIS
to IDC remain unexamined.
Recent studies have highlighted the role of the micro-
environment in the transition from DCIS to IDC [14–
16]. During the transition from DCIS to IDC, epigenetic
changes have been observed in stromal cells, including
fibroblasts and myoepithelial cells [17], suggesting that
the microenvironment plays a relevant role. The tumour
microenvironment may be modulated by stress response
factors such as hormones and neuronal factors [18]. In
fact, the effect of stress-related neuroendocrine factors
on breast cancer progression has been addressed by sev-
eral research groups including ours [19–21]. However,
the impact of these molecules in the transition from
DCIS to IDC has not yet been studied. Thus, under-
standing how stress and associated neuronal factors
affect the biology of DCIS and, in particular, the fate of
myoepithelial cells, could be relevant to clinical manage-
ment and outcomes.
Glucocorticoids are one of the most important neuronal
factors involved in the stress response, and are implicated
in other physiological functions, such as the inflammatory
response and glucose metabolism regulation [22]. Gluco-
corticoids are lipophilic molecules and diffuse across the
cell membrane. They act through their intracellular gluco-
corticoid receptors (GR) and mineralocorticoid receptors,
although it is suggested they induce tumour progression
activity in a GR-dependent manner [23].
Cortisol and corticosterone are the two major gluco-
corticoids present in humans. Blood corticosterone levels
are 10–20-fold lower than cortisol, but corticosterone
represents almost 40% of total active glucocorticoids in
cerebrospinal fluid [24]. Corticosterone is the major
glucocorticoid in rodents and has been related to cancer
progression in animal models [25], although its role in the
context of DCIS invasiveness is unknown.
Cortisol, the major glucocorticoid found in humans,
generates a physical response to the stress signal by
binding to its receptor, GR. Cortisol plays an important
role in mammary gland development [26] and function
and therefore increased levels caused by stress may
affect the fate of the mammary tissue. In addition, corti-
sol has an impact on oestrogen activity in the mammary
gland, inducing aromatase activity [27] and regulating
breast cancer [19]. Cortisol is an immunomodulator that
reduces the immune system’s ability to detect and re-
spond to tumour cells [19, 28], acts on DNA repair
mechanisms, and modulates apoptosis [19, 23, 29].
GR is expressed in healthy breast tissue and in breast
cancer, including DCIS and IDC [30]. GR expression di-
minishes with breast cancer progression and thus is
higher in DCIS than in IDC [30]. Moreover, the GR an-
tagonist, RU486 or mifepristone, has been suggested to
be a normal breast epithelium protector [31], and in this
context, there is an ongoing clinical trial based on the
activity of RU486 in patients with breast cancer genes 1/
2 (BRCA1/2) (clinical trial identifier NCT01898312).
Additionally, pathological studies have found that myoe-
pithelial cells express higher levels of GR than epithelial
cells [30]. However, studies of the function of cortisol in
the fate of myoepithelial cells and in the regulation of
DCIS invasiveness are lacking. The purpose of this study
was to investigate the effects of glucocorticoids on the
transition from DCIS to IDC, paying special attention to
myoepithelial cell modulation. Interestingly, our studies
demonstrate that glucocorticoids foster the transition
from DCIS to IDC through the induction of myoepithe-
lial cell apoptosis and the reduction in laminin levels in
in vitro and in vivo stress model experiments. Further-
more, in patients with breast cancer, myoepithelial cell
apoptosis is more frequent in patients with DCIS+IDC
than in patients with DCIS, implying this process may
be a key factor in the evolution from DCIS to IDC.
Methods
Cell culture
MCF10DCIS (Asterand, MI, USA) and MCF10A
(American Type Culture Collection (ATCC), VA, USA)
human mammary cell lines were cultured at 37° in a hu-
midified atmosphere with 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium nutrient mixture-F12 (DMEM-F12)
(Gibco, Life Technologies, CA, USA), supplemented
with 1% of L-GlutaMAX™ 200 mM (Gibco, Life Tech-
nologies CA, USA), 100 U/mL penicillin, 100 μg/mL
streptomycin and 5 μg/mL Fungizone (PSF) (Gibco, Life
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Technologies CA, USA), 5% of horse serum (Gibco, Life
Technologies CA, USA) and, specifically, for MCF10A,
20 ng/mL epithelial growth factor (EGF) (Peprotech, NJ,
USA), 0.5 μg/mL hydrocortisone (Sigma, MO, USA),
10 μg/mL insulin (Sigma, MO, USA) and 100 ng/mL
cholera toxin (Sigma, MO, USA) were also added.
Primary myoepithelial cells and epithelial cells were
isolated from fresh healthy mammary tissue from five
women aged 20–45 years (Additional file 1: Table S1).
Samples were obtained under the approval of the Insti-
tutional Review Board of the Hospital Clinic and Clinica
Planas, Barcelona. To obtain mammary myoepithelial
cells, epithelial cells and organoid fractions were cul-
tured in M87A medium [32] (see Additional file 2). Cell
sorting of CD10+ cells from epithelial and organoid frac-
tions was used to isolate myoepithelial cells, as described
by LaBarge and colleagues [33].
Cell viability
To analyse in vitro cell viability, 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT) assays (Promega,
WI, USA) were performed. Briefly, 1.5*104 cells/100 μL
were seeded per well in MW96 plates. After 24 h, cells
were treated for 48 h with increasing concentrations of
cortisol (0.1, 0.25, 0.5, 1, 2.5, 5 and 10 μM), corticosterone
(0.125, 0.25, 0.375, 0.5, 0.75, 1, 1.25 and 1.5 μM) or with
the corresponding vehicle concentration (methanol). The
analysis was carried out following the kit instructions
(Promega, WI, USA). Absorbance was measured immedi-
ately using a microplate reader spectrophotometer
(Sinergy, Bio Tek, VE, USA). Measurements were made at
492 nm (test wavelength) and at 620 nm (reference wave-
length), to correct for noise.
Cell cycle
Cell cycle was analysed using bromodeoxyuridine
(5-Br-2′-deoxyuridine or BrdU): 2*105 cells were seeded
in p60 dishes and when 70% of cell density was achieved
cells were treated with 0.7 μM of cortisol or vehicle
(methanol). After 48 h the cells were treated with 10 μM
BrdU for 5 h. Subsequently, BrdU (10 μM) was added to
each well and left to be incorporated into the newly syn-
thesized DNA of replicating cells for 3 h. Cells were har-
vested with PBS and fixed with ethanol O/N. The next
day, cells were permeabilized and denaturalized by HCl
2 M and 0.5% Triton X-100 for 1 h at room temperature
(RT); 0.1 M Na2B4O7 was then used to neutralize HCl
for 20 min at RT. Anti-BrdU-fluorescein isothiocyanate
(FITC) antibody (1:20, #F7210, Dako, Denmark) was
added and the mixture kept in the dark for 1 h after PBS
washing. Next, cells were suspended in 500 μL of propi-
dium iodide (PI) buffer (PBS, 0.4 mg/mL RNase A,
0.2 μg/mL PI) and incubated in darkness for 15−20 min.
The cells were analysed by flow cytometry (BD LSRFortessa)
and the results evaluated by FACSDiva software (Becton-
Dickinson, NJ, USA).
Cell apoptosis
To determine cell apoptosis, an Annexin V assay (BD
Annexin V: FITC Apoptosis Detection Kit I, (BD Biosci-
ences, CA, USA) was performed in semi-confluent cell
cultures: 3*105 cells were seeded in p60 dishes until the
plates were 70% confluent. The cells were then treated
with 0.1, 0.25 and 1 μM cortisol or with 0.25, 0.6 and
1 μM of corticosterone for 48 h or vehicle (methanol).
The assay was performed following the manufacturer’s in-
structions (BD Biosciences, CA, USA) and analysed using
flow cytometry (FORTESSA LSR, Becton-Dickinson, NJ,
USA). The results were evaluated by FACSDiva software
(Becton-Dickinson).
Three-dimensional cell culture
The functional characteristics of the cells and their abil-
ity to form proper acinar structures were evaluated by
three-dimensional (3D) cultures using BD Matrigel™
Basement Membrane Matrix (BD Biosciences, CA, USA)
under corticosterone and cortisol treatment. On-top 3D
cell cultures were made in MW24 plates and 1*105 of a
mix of primary epithelial and myoepithelial cells/well
were seeded in 500 μL of M87A medium supple-
mented with 4% of matrigel on a matrigel pre-coated
MW24 well. Medium was changed three times per
week and 1 mL of M87A medum with 4% of matrigel
was added to each well. Cells were seeded on top of
matrigel cultures and treatment was started after
5 days. Briefly, the cell medium was discarded and
new M87A medium was mixed with the desired
amount of the molecule of interest and 4% of matrigel
on ice. Cortisol 0.7 μM, corticosterone 1 μM and
RU486 0.5 μM (Sigma, MO, USA) was used as treat-
ment. Treatment was administered three times per
week until day 14 after seeding.
In vivo experiments
In vivo experiments were performed in female NUDE
mice aged 3–4 weeks that were bred at the medical
school’s animal facility laboratory and kept under spe-
cific pathogen-free conditions at constant ambient
temperature (22–24 °C) and humidity (30–50%). The
mice had access to sterilized food and tap water ad libi-
tum. In vivo experiments were performed according to
Catalan Government Animal Experimentation Ethics
Committee regulations (Comitè Ètic d’Experimentació
Animal(CEEA)).
The MCF10DCIS cell line, which forms DCIS in mice
and spontaneously evolves to invasive carcinoma, was
used [18]. Mice were anaesthetized using ketamine/xyla-
zine to inoculate the mammary fat pad with cancer cells:
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105 cells diluted in PBS-matrigel (BD Biosciences, CA,
USA) (1:1) were then injected orthotopically into each
mouse mammary fat pad with a total volume of 100 μL.
In vivo time course
Tumour growth and animal weight were monitored
twice a week for 29 days after MCF10DCIS inoculation.
Mice were killed at days 7, 22 and 29 after inoculation.
Tumours were extracted, fixed in paraformaldehyde
(PFA) 4% and stored as paraffin-embedded tissue.
In vivo immobilization stress model
Mice were subjected to immobilization stress 7 days
after inoculation of MCF10DCIS cells into the mammary
fat pad. Briefly, mice were placed into 50-mL Falcon
tubes where various holes ensured proper ventilation for
2 h, 5 days per week, for 3 weeks [34, 35]. We consider
our in vivo stress model a chronic stress model because
acute stress is a type of punctual and short-term stress
[36]. On the other hand, chronic stress implies a more
repetitive and/or long-term exposure to the stress source
[37]. In parallel, blood was extracted from the mouse tail
vein twice per week, starting before the inoculation of
cells and continuing until sacrifice. Blood was extracted
using EDTA-coated eppendorf tubes (Microvette® CB
300, Sarstedt, Germany), kept on ice and then centri-
fuged at 10,000 rpm for 5 min at 4 °C. Plasma was re-
covered and stored at − 80 °C.
Corticosterone ELISA in stress experiments in vivo
Circulating levels of corticosterone in murine plasma
were measured using an ELISA kit according to the
manufacturer’s instructions (Abnova, China). Colour in-
tensity was measured at 450 nm in a spectrophotometer
(Sinergy, BioTek, VE, USA). Corticosterone levels were
determined using a standard sigmoidal curve and com-
paring it with the standard curve.
In vivo chicken embryo model
The chicken chorioallantoic membrane (CAM) model
has been previously described [38–40]. For the CAM xe-
nografts we used premium specific pathogen-free (SPF),
fertile, 9-day- incubated embryonated chicken eggs sup-
plied by Gibert farmers: 2*106 MCF10DCIS cells diluted
in PBS and matrigel were inoculated on CAMs and tu-
mours were grown for 6 days. The day after inoculation,
the tumours were treated with cortisol 0.7 μM or/and
RU486 0.5 μM for 5 days. On day 6 after inoculation the
tumours were excised, weighed, measured and immedi-
ately fixed in 4% formaldehyde to perform IF analysis.
Immunofluorescence
To carry out immunofluorescence in 2D cell culture
systems, cells were seeded on coverslips, incubated at
37° for 24 h and treated for 24 h with 0.7 μM cortisol
and 1 μM corticosterone. Immunofluorescence of K14
(1/100, #ab9220, Abcam, UK), K19 (1/10, #Troma-III,
DSHB, IA, USA) and for GR distribution studies (1/100,
#PA-1-511A, Thermo Fisher Scientific, MA, USA) was
carried out as previously described [41]. After washing,
secondary antibodies were added and cells were counter-
stained with Hoechst dye 2 μg/mL (Life Technologies,
CA, USA) for 15 min at RT in a dark humidified cham-
ber. Cell coverslips were mounted using ProLong® Gold
antifade reagent (Life Technologies, CA, USA).
Three-dimensional immunofluorescence was carried
out in 3D cell cultures for 14 days after 8 days treatment
with cortisol 0.7 μM, corticosterone 1 μM and RU486
0.5 μM as previously described [41]. K14 (1/100), K19 (1/
10) and laminin (1/100, #ab11575, Abcam, UK) were used
as primary antibodies. Muc1-FITC (#559774, Becton
Dickinson, NJ, USA) was used as primary antibody to
counterstain epithelial cells. Incubation with secondary
antibodies was sequentially applied after washing. Samples
were then counterstained with Hoechst dye 2 μg/mL (Life
Technologies, CA, USA) for 15 min and analysed by con-
focal microscopy (Leica TCS-SP5 Broadband Confocal
and Multiphoton Microscope). Additionally, we per-
formed immunofluorescence of α-smooth muscle actin
(α-SMA) (1/100, #M0851, Dako, Denmark) in the tumour
sections. Briefly, the slides were incubated at 65 °C for
30 min and hydrated following a decreasing ethanol gradi-
ent (100–70%). Then, citrate buffer (pH = 6.0) was used
for immunoreactivity enhancement. The primary and sec-
ondary antibody incubation was performed as described
above for the 2D immunofluorescence.
Immunohistochemical analysis
Immunohistochemical analysis of tumour samples stored
as paraffin-embedded tissue was carried as previously de-
scribed [42]. Laminin (1/100) and cleaved caspase 3 (1/100,
#9664S, Cell Signaling, MA, USA) antibodies were used.
Depending on the technique performed and the manufac-
turer’s specifications, different antibodies were used to de-
tect myoepithelial cells: CD10 (1/100, #M7308, Dako, CA,
USA), p63 (1/100, #sc-8431, Santa Cruz Biotechnologies,
TE, USA) and αSMA (1/100) were used as primary anti-
bodies. After washing the samples were incubated in the
presence of HRP-conjugated secondary antibodies. After
washing, samples were incubated with Vectastain ABC for
30 min in a humidified chamber followed by incubation in
the presence of DAB substrate (FAST™ 3,3′-diaminobenzi-
dine tablets, Sigma) for 5–10 min at RT, monitoring colour
development by microscopy. Slides were washed with water
and counterstained in 1:3 Gill II haematoxylin (Panreac) for
1 min. The slides were mounted with Cytoseal™ 60
(Thermo Scientific), left to dry and analysed by phase
contrast microscopy.
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Double immunofluorescence in paraffin-embedded tissue
The first steps for double immunofluorescence in
paraffin-embedded tissue were identical to those of the
immunohistochemical analysis. Deparaffinization and re-
hydration were carried out followed by antigen retrieval,
as previously described [42]. After cooling, samples were
washed with PBS and blocked with 10% normal goat
serum in PBS for 10 min at RT. The primary antibodies,
p63 (1/100) and cleaved caspase 3 (1/100) or laminin (1/
100) were diluted in 5% normal goat serum in PBS and
the mix was incubated for 2 h at RT in a humid box.
After washing, the mix was incubated with secondary
antibodies for 1 h at RT in a dark humid box. Slides
were counterstained with Hoechst dye 2 μg/mL (Life
Technologies, CA, USA) for 15 min in a dark humid
box. Finally, samples were mounted with ProLong® Gold
antifade reagent (Life Technologies, CA, USA) and ana-
lysed using fluorescence microscopy.
Patient samples
Samples from patients with DCIS or DCIS+IDC were ob-
tained from the Biobank of the Hospital Clinic of Barce-
lona, Institut d’Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS), after Institutional Ethics Committee
approval. Thirteen samples from patients with DCIS and
fifteen from patients with DCIS+IDC were used (lesions
specified in Additional file 3: Table S2). Myoepithelial cell
layer apoptosis was evaluated using immunohistochemical
analysis of CD10 (1/100) and double immunofluorescence
of cleaved caspase 3 (1/300) and p63 (1/100).
Statistical analysis
The results were plotted and analysed using GraphPad
Prism7 software (CA, USA). The Mann-Whitney test,
Wilcoxon paired test and one-way analysis of variance
(ANOVA) followed by a post-hoc test were used accord-
ing to the type of analysis.
Results
Cortisol inhibits myoepithelial cell growth through
induction of cell cycle arrest and apoptosis
To study the effect of glucocorticoids on myoepithelial
cells, we used human myoepithelial primary cell cultures
isolated from reduction mammoplasties [41]. Since
primary epithelial cells are difficult to maintain in cul-
ture, we used the MCF10A cell line as representative
of the epithelial population. Another epithelial cell line,
MCF10DCIS, which spontaneously generates DCIS
when transplanted into mice [18], was also used. First,
we tested the expression of glucocorticoid receptors
in epithelial, myoepithelial and MCF10DCIS cells
(Additional file 4: Figure S1). We found that all cell lines
express the glucocorticoid receptor (GR), and that
myoepithelial cells express higher levels than MCF10A
or MCF10DCIS.
Two-dimensional myoepithelial cells and epithelial cell
cultures were then treated with different concentrations
of cortisol for 48 h. MTT assays showed that myoepithe-
lial cell survival was reduced dose-dependently in the
presence of cortisol, reaching a reduction of almost 50%
at the highest tested dose (Fig. 1a). Epithelial MCF10A
cell growth was also slightly more attenuated after treat-
ment with cortisol (Fig. 1a), suggesting it affects the pro-
liferation of both epithelial and myoepithelial cell
growth. MCF10DCIS epithelial cells were resistant to
cortisol (Fig. 1a) at the maximum doses tested.
Since cortisol inhibits myoepithelial cell growth we
used a BrdU assay to analyse its effect on the cell cycle.
We found that treatment with cortisol arrested myoe-
pithelial cells in both the G1 and G2 phases, further de-
creasing the number of cells undergoing the S phase
(Fig. 1b-c). In contrast, in MCF10A cells, only a very
small percentage of cells were arrested in the G2 phase
and there was no arrest in the G1 phase. Therefore, the
reduction in cells in the S phase was not as prominent
as in the case of myoepithelial cells (Fig. 1b-c). These re-
sults suggest that myoepithelial cells are more suscep-
tible than epithelial cells to the effects of cortisol on
their cell cycle. Thus, cortisol inhibits epithelial and, in a
stronger way, myoepithelial cell growth partially through
the induction of cell cycle arrest.
However, the effect of cortisol on the cell cycle did not
explain the differences in survival between myoepithelial
and epithelial cells after glucocorticoid treatment. There-
fore, we also investigated the induction of apoptosis by
glucocorticoids. We used an Annexin V binding assay to
determine whether these cells were undergoing apop-
tosis and found that myoepithelial cell apoptosis in-
creased in a dose-dependent manner by around 15%
(Fig. 1d): however, the percentage of apoptotic cells was
always below 5% for MCF10A epithelial cells and the
MCF10DCIS cell line (Fig. 1d). Thus, we speculate that
the induction of apoptosis might explain the reduction
observed in the survival of myoepithelial cells after
glucocorticoid treatment, an effect that seems to be re-
stricted to the myoepithelial cell lineage.
Cortisol hampers the formation of 3D acinar-like
structures in vitro
After observing that glucocorticoids inhibited the pro-
liferation of myoepithelial cells by causing apoptosis
and cell cycle arrest, we studied how glucocorticoids
influenced the formation and structure of 3D acini
using on-top matrigel cultures of a mix of healthy
primary mammary epithelial cells and myoepithelial
cells that, when grown in 3D systems, can form
acinar structures [41].
Zubeldia-Plazaola et al. Breast Cancer Research  (2018) 20:65 Page 5 of 16
We seeded the cells on matrigel and let the acini grow
for 5 days before treating them with cortisol for 9 days.
Subsequently, we searched for epithelial cell (cytokeratin
19) and myoepithelial cell (cytokeratin 14) marker expres-
sion. We found that cortisol affected the capacity of
epithelial and myoepithelial mammary cells to form acinar
structures because the number of acini was smaller than
in untreated cell cultures (Fig. 2a). In addition, cortisol
treatment seems to disrupt the myoepithelial cell layer, as





Fig. 1 Cortisol effects on myoepithelial, MCF10A and MCF10DCIS cell viability, cell cycle and apoptosis. a Cell viability evaluation by 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay after 48 h of increasing doses of cortisol treatment (0.1–10 μM). b Cell cycle distribution was determined
by bromodeoxyuridine (BrdU)-fluorescein isothiocyanate (FITC) and Propidium iodide (PI) assay after 48 h of treatment with cortisol 0.7 μM or vehicle
(methanol) and evaluated by flow cytometry. c Graphic representation of cell cycle distribution in percentages by the population evaluated. d Cell apoptosis
in its different stages (early apoptosis, apoptosis and late apoptosis) was determined after cortisol treatment with 0–1 μM doses by the Annexin V method
and measured by flow cytometry. All experiments were carried out in triplicate. The Mann-Whitney test was used for statistical analysis




Fig. 2 Influences of cortisol treatment on 3D growth of mammary epithelial cells for 14 days identified by immunofluorescence. Cells were
treated with cortisol 0.7 μM or vehicle (methanol) from day 5 after seeding until day 14. a Upper panels: immunodetection in primary epithelial
and myoepithelial cells of K14 (myoepithelial cells), K19 (epithelial cells) and Hoechst dye was used as nuclei counterstaining. Scale bar = 50 μm.
Bottom panels: quantification of morphometric analysis in the control group and cortisol-treated group of the number of acini formed and
quantification of disrupted acini per total number of acini. b Upper panels: immunofluorescence of laminin (BM), cytokeratin14 (myoepithelial
cells) and Hoechst dye to counterstain nuclei. Scale bar = 100 μm. Bottom panels: quantification by Image J software of laminin intensity after
cortisol 0.7 μM or vehicle treatment. c Immunofluorescence in MCF10DCIS 3D growth of laminin (basement membrane), Muc1 (epithelial cells)
and Hoechst dye to stain the nuclei under control (vehicle), cortisol 0.7 μM, RU486 0.5 μM and cortisol 0.7 μM+ RU486 0.5 μM. Arrows indicate
rupture points of the acini. d Morphometric quantification of disrupted acini and acinar fusion and intensity of laminin determined by the
integrated density parameter of Image J software. Scale bar = 50 μm. All experiments were carried out in triplicate. Statistical analysis was
performed using the Mann-Whitney test or one-way analysis of variance followed by Tukey post-hoc test
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(Fig. 2a). To further study myoepithelial cell layer disrup-
tion, we also stained the 3D structures for laminin, the
principal component of the BM, which is usually pro-
duced by myoepithelial cells [10]. We found that, when
treated with cortisol, the amount of laminin surrounding
the acini was significantly reduced (Fig. 2b). This suggests
that when treated with cortisol, the acini acquire a more
invasive phenotype and that apoptosis or cell cycle arrest
of myoepithelial cells might in part be responsible for
myoepithelial layer disruption (Fig. 2a-b). These results
are in agreement with our 2D results, since apoptosis of
myoepithelial cells caused by cortisol may affect their cap-
acity to form duct-like structures and would favour inva-
sion by disrupting the myoepithelial cell layer.
We made 3D cultures of MCF10DCIS cells and treated
them with cortisol to determine whether this molecule has
the same effect on MCF10DCIS cells, which were resistant
to cortisol in MTT experiments (Fig. 1a, Fig. 2c-d). After
treatment with cortisol, laminin intensity decreased and the
proportion of acinar fusion increased (Fig. 2c-d), suggesting
that treatment with cortisol also promotes the invasive cap-
acity of DCIS acinar-like structures. Additionally, treatment
with the GR antagonist, RU486, was able to block the ef-
fects of cortisol on the functional abilities of the
MCF10DCIS 3D cultures (Fig. 2c-d). In fact, it prevented
cortisol induction of acinar fusion and disruption (Fig. 2c-d).
However, RU486 treatment only partially prevented cortisol
inhibition of laminin levels (Fig. 2c-d). These results suggest
that cortisol via its receptor GR is responsible for the accel-
eration of MCF10 DCIS acquisition of invasive features.
Glucocorticoids accelerate the progression of DCIS to IDC
in vivo by inducing myoepithelial cell layer disruption
To better understand the role of myoepithelial cells in
the progression of breast cancer and to study the dy-
namics of the formation and disruption of the myoe-
pithelial layer under stress, we established an in vivo
model using immunosuppressed mice and the
MCF10DCIS cell line, which generates DCIS when inoc-
ulated into immunosuppressed mice and then evolves to
IDC [18]. First, we established the dynamics of the for-
mation and disruption of the myoepithelial cell layer in a
control situation (Additional file 5: Figure S2A). We in-
oculated 105 cells in the mammary fat pad of mice that
were subsequently killed at different times (Additional
file 5: Figure S2A). Tumours were fixed and stored as
paraffin-embedded tissue to study the tumour histology
with haematoxylin and eosin staining (H&E) and by im-
munohistochemical analysis using antibodies against the
myoepithelial cell markers alpha-smooth muscle actin
(αSMA) and p63 (Additional file 5: Figure S2A).
The results showed that the first duct-like structures,
surrounded by a layer of cells positive for αSMA and
p63 (Additional file 5: Figure S2A), were formed at day 7
after inoculation of MCF10DCIS cells. At day 22, the
myoepithelial cell layer was widely ruptured and by day
29 duct organization was virtually lost. At this point,
some αSMA-positive cells were tumour-associated fibro-
blasts, while a subset of tumour epithelial cells was p63
positive (Additional file 5: Figure S2A). To investigate
whether MCF10DCIS epithelial or myoepithelial cells
could respond to glucocorticoids in vivo, we analysed
the expression of GR in these tumours and found that
both epithelial and myoepithelial cells expressed GRs
(Additional file 5: Figure S2B).
Since corticosterone is the glucocorticoid expressed in
mice, we determined whether it had the same effects as cor-
tisol (Additional file 6: Figure S3) and found that it inhibited
proliferation in myoepithelial cells and to a lesser extent in
MCF10A cells while MCF10DCIS cells were also resistant
to corticosterone (Additional file 6: Figure S3A). Further-
more, similar to cortisol, treatment with corticosterone in-
duced apoptosis only in myoepithelial cells (Additional
file 6: Figure S3B). Moreover, corticosterone treatment also
induced the disruption of 3D culture acini and inhibited
laminin expression in a co-culture of primary epithelial and
myoepithelial cells and also in the MCF10DCIS cell line
(Additional file 6: Figure S3C-F). These results suggest that
corticosterone might promote invasiveness through myoe-
pithelial cell apoptosis, as did cortisol.
To determine whether glucocorticoids promote DCIS
transition to IDC, MCF10DCIS cells were inoculated
into mice mammary fat pads, and 9 days later when
DCIS was established immobilization stress was initiated
to mimic chronic stress (Fig. 3a). Blood was extracted
from mice tails every 3 days and corticosterone levels
were measured using ELISA (Fig. 3a-b). We have previ-
ously found that in vitro corticosterone treatment of
MCF10DCIS cells produces similar effects to cortisol on
cell viability, apoptosis and functional 3D abilities
(Fig. 2c-d and Additional file 6: Figure S3A-B), favouring
the breakdown of the myoepithelial cell layer and the
disappearance of the BM in a similar fashion to cortisol.
Mice underwent stress daily until they were killed at
24 days after inoculation, when the myoepithelial cell
layer was mostly ruptured (Fig. 3c). Tumours were ex-
tracted, fixed and stored as paraffin-embedded tissue. As
expected, corticosterone levels significantly increased
when stress began and remained elevated throughout
the experiment (Fig. 3b).
To determine how the architecture of duct-like structures
changed in control and stressed mice tumours, histology
was examined by H&E staining and immunohistochemical
analysis was performed using antibodies against the myoe-
pithelial cell and basement membrane markers α-SMA and
laminin (Fig. 3c-d). We found that although the ducts in
both control and stressed tumours were starting to rupture,
there was greater disorganization of the ductal architecture






Fig. 3 In vivo stress model and the effects on evolution of the MCF10DCIS xenograft. a Timeline of the in vivo stress model indicating blood
extraction and the immobilization method applied. b Corticosterone levels (ng/ml) in plasma samples obtained at different points of the in vivo
stress model in mice, in the control and stressed group of MCF10DCIS xenograft. The Wilcoxon paired test was used for statistical analysis. c Left
panel: representative image of α-smooth muscle actin (α-SMA, a myoepithelial cell marker) from immunohistochemical analysis of the control and
stressed tumours in mice. Scale bar = 50 μm. c Right panel: duct size quantification by Image J Software. In vivo experiments were performed
using five animals per group. The Mann-Whitney test was used for statistical analysis. d Left panel: representative laminin immunohistochemical
images in control and stressed MCF10DCIS xenografts. Scale bar = 50 μm. d Right panel: laminin and p63 double immunofluorescence and
quantification of laminin intensity images (Image J Software) of tumours derived from control and stressed mice. Hoechst dye was used to
counterstain the nuclei. Scale bar = 20 μm. e Left panel: representative cleaved caspase 3 immunohistochemical image of a tumour from stressed
mice. Scale bar = 20 μm. e Middle panel: representative cleaved caspase 3(green) and p63(red) immunofluorescence image of a tumour
from stressed mice. Hoechst dye was used as the counterstain for nuclei. Scale bar = 20 μm. e Right panel: quantification of caspase 3-positive
myoepithelial cells per duct in control and tumours from stressed mice; n = 5 animals/group. The Mann-Whitney test was used for statistical
analysis. DCIS, ductal carcinoma in situ
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when mice underwent stress (Fig. 3c-d), and the ducts were
significantly larger in the tumours of stressed animals, sug-
gesting they may have been disrupted earlier, joining to-
gether and forming larger ductal structures (Fig. 3c-d).
To determine how stress affected the invasiveness of
DCIS, BM loss was also analysed by laminin staining, a
key feature of invasiveness. Laminin immunohistochemi-
cal and double immunofluorescence assays, together with
p63 staining, were used and the results showed stressed
mice had significantly less laminin surrounding the ducts
(Fig. 3d), thus showing a more invasive phenotype.
As the treatment of myoepithelial cell cultures with
corticosterone in vitro caused apoptosis (Additional
file 6: Figure S3B), we analysed the number of apoptotic
myoepithelial cells per duct and found more apoptotic
myoepithelial cells in tumours from stressed mice, who
were thus exposed to higher corticosterone levels
(Fig. 3e).
These results may suggest that chronic stress through
sustained high blood corticosterone levels and other
mechanisms promotes myoepithelial cell apoptosis, lead-
ing to disruption of the myoepithelial cell layer, favouring
cell invasion and fostering progression from DCIS to IDC.
Additionally, we used the chick embryo chorioallantoic
membrane (CAM) system for growing MCF10DCIS tu-
mours (Fig. 4a). First of all, we tested whether when in-
oculated in CAM, MCF10DCIS form the same
structures as they do in xenografts on mice (Add-
itional file 7: Figure S4). The double p63 and laminin
immunofluorescence carried out in the tumour sections
showed typical organization of MCF10DCIS tumour
growth and a proper laminin and p63 distribution (Add-
itional file 7: Figure S4). Thus, we have used this model
to study the effects of cortisol and the GR antagonist,
RU486, on the transition of MCF10DCIS tumours to
IDC in vivo (Fig. 4). Our results have shown that cortisol
treatment slightly increases tumour volume, while treat-
ment with cortisol and RU486 partially reverts this
effect. In a similar way, treatment with cortisol induces
acinar fusion and increases acini size (Fig. 4d-e). Fur-
thermore, the myoepithelial cell layer detected by stain-
ing of αSMA positive cells was reduced after cortisol
treatment (Fig. 4f ). Interestingly, treatment with GC
antagonist alone slightly increases αSMA staining. How-
ever, combination of cortisol and RU486, not only
reverted cortisol inhibition of αSMA and disruption of
the myoepithelial cell layer, but also prevented cortisol
induction of acinar fusion and reduced acini size
(Fig. 4d-f ).
We also quantified myoepithelial cell apoptosis
(Fig. 4g-h). In agreement with our previous in vitro re-
sults, the number of apoptotic myoepithelial cells was
increased after treatment with cortisol. Interestingly,
RU486 treatment partially reverted the effects of cortisol
on myoepithelial cell apoptosis (Fig. 4g-h). Thus, treat-
ment with RU486 in vivo hampers cortisol induction of
acinar fusion, degradation of the BM and myoepithelial
cells apoptosis, preventing cortisol promotion of DCIS
invasiveness.
Myoepithelial cell fate in patients with DCIS and DCIS+IDC
As we have found that myoepithelial cell apoptosis contrib-
utes to disruption of the myoepithelial cell layer and the BM
and promotes the invasiveness of DCIS, we wondered if pa-
tients with DCIS+IDC would have more apoptotic myoe-
pithelial cells in the ducts, indicating a more invasive DCIS
phenotype. Therefore, we obtained breast tissue samples
from patients with DCIS or DCIS+IDC and evaluated
myoepithelial cell apoptosis. We analysed tissue samples
from 13 patients with DCIS and 15 patients with DCIS
+IDC (Additional file 3: Table S2) with both immunohisto-
chemistry against CD10 (myoepithelial cells) (Fig. 5a) and
double immunofluorescence against p63 (myoepithelial
cells) and cleaved caspase 3 (apoptosis marker) (Fig. 5b-c
and Additional file 8: Figure S5). The results showed that
patients with DCIS+IDC lost most of the continuous p63
staining (Fig. 5b bottom part, 5C and Additional file 8:
Figure S5) and exhibited myoepithelial cell apoptosis in
some ducts, whereas patients with DCIS did not present
apoptosis of myoepithelial cells in most ducts, although iso-
lated apoptotic events were detected (Fig. 5b upper part, 5C
and Additional file 8: Figure S5), suggesting myoepithelial
cell apoptosis is a prerequisite for DCIS invasiveness (Fig. 6)
and that the use of RU486 could partially prevent this event.
Discussion
Understanding the mechanisms that initiate and trigger
DCIS invasiveness is relevant because understanding how
DCIS evolves into invasive carcinoma could enable the de-
sign of interventional strategies to prevent breast cancer
progression. The most widely accepted hypothesis on the
mechanisms regulating the transition from DCIS to IDC
suggests the microenvironment is involved, in particular fi-
broblasts and myoepithelial cells [14, 15, 43]. Despite recent
progress in myoepithelial cell research suggesting that they
may act as tumour suppressors [11], the mechanism of
myoepithelial cell layer disruption remains elusive.
In this scenario, the present study investigated the role
of glucocorticoids in the transition of DCIS to invasive-
ness. The effect of stress-related factors, studied as
microenvironmental elements, in the progression of
breast cancer has been investigated [18, 44]. However,
the impact of glucocorticoids in the transition from
DCIS to IDC has not yet been studied. To the best of
our knowledge, this is the first study to suggest that glu-
cocorticoids contribute to the transition from DCIS to
IDC, particularly through the disappearance of the basal
lamina and the induction of myoepithelial cell apoptosis.
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In addition, myoepithelial cell apoptosis is prominent in
breast cancer tumours that have progressed to IDC, sug-
gesting apoptosis could be a preliminary, essential factor
that precedes invasiveness.
Glucocorticoids have been shown in studies to mediate
growth inhibition in some mammary tumour cell lines
[45], and to induce G1/G0 cell cycle arrest [46], and if






Fig. 4 In vivo chicken embryo chorioallantoic membrane (CAM) system for growing MCF10DCIS tumours. a Timeline of CAM model indicating how the
inoculation of MCF10DCIS cells was performed and how the tumours were treated. b Representative tumour images after treating with control, cortisol
0.7 μM, RU486 0.5 μM and cortisol + RU486 for 5 days. c Graphical representation of tumour volume in mm3. d α-Smooth muscle actin (α-SMA) (in red)
immunofluorescence of the tumours after treatment with cortisol 0.7 μM, RU486 0.5 μM and cortisol + RU486. Hoechst dye was used to counterstain
nuclei. Scale bar =20 μm. e Quantification of acini size (μm). Bottom panel: representation of percentage of α-SMA-positive area in tumours. Scale bar =
50 μM. f Images of double p63 (myoepithelial cells) and cleaved caspase 3 immunofluorescence in tumours. Scale bar = 50 μM. g Graphical representation
of apoptotic myoepithelial cells quantification in tumours under the different treatments. One-way analysis of variance was used for statistical analysis
followed by Tukey post-hoc test
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However, there are contrasting results on the effect of
glucocorticoids on cell survival and proliferation [45,
48]. For instance, in breast invasive tumours, glucocorti-
coids promote cell survival through the induction of
anti-apoptotic genes [29]. In contrast, glucocorticoids
trigger apoptosis in hematopoietic cells and lymphocytes
[28], suggesting they may act differently depending on
the cell subtype. GRs are expressed in luminal epithelial
cells and occasionally in stromal cells, but predomin-
antly in myoepithelial cells [30], suggesting that GR are
expressed in a cell-lineage-dependent manner in breast
tissue [30] as reported in other tissues [45, 46], and that
myoepithelial cells may play a physiological role in medi-
ating the effects of glucocorticoid hormones in the
breast.
Furthermore, our results showed that glucocorticoids
induce the degradation of the BM and the disruption of
acinar structures through a significant loss of laminin in
healthy human mammary epithelial and myoepithelial
cells and in MCF10DCIS 3D cultures. Laminin is a
prominent and influential component of the BM, which




Fig. 5 Immunohistochemical and immunofluorescence images of human samples from patients with ductal carcinoma in situ (DCIS) and DCIS +
invasive ductal carcinoma (IDC). a CD10 (myoepithelial cells) immunohistochemical analysis of samples from patients. Scale bar = 100 μm. b Double
immunofluorescence of p63 (myoepithelial cells) and cleaved caspase 3 and Hoechst dye as a nuclei counterstain. Upper panel: patients with DCIS;
bottom panel: patients with DCIS + IDC. White scale bar = 20 μm and red scale bar = 50 μm. c Quantification of apoptotic myoepithelial cells in DCIS
(13 patients) and DCIS + IDC (15 patients). The Mann-Whitney test was used for statistical analysis
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[49–51]. Laminin expression and αSMA levels are both
related to tumour malignancy [52, 53]. Similarly, our in
vivo stress model and our in vivo chicken embryo CAM
system showed indicators of higher invasiveness after
stress challenge [10], in particular increased acinar rup-
ture and reduced laminin levels or αSMA levels. More-
over, treatment of MCF10DCIS 3D cultures with the GR
antagonist, RU486, blocked the effects of cortisol on the
integrity of the acinar structures and also on the BM,
highlighting the influence of cortisol on the early acqui-
sition of invasive features in breast cancer cells. We
hypothesize that the loss of laminin is directly related to
myoepithelial cell loss by apoptosis. However, more ex-
periments are needed to confirm this idea.
In this context, repeated immobilization has been de-
scribed as a model of chronic stress since in our case it
was applied for 2 h every day for a period of 4 weeks. In
addition, the repeated immobilization model is reported
to increase corticosterone plasma levels among other
changes [54]. In fact, chronic stress situations initiate a
cascade of pathways in the central nervous system and
periphery, triggering fight-or-flight stress responses in
the autonomic nervous system (ANS) or defeat/with-
drawal responses in the hypothalamic-pituitary-adrenal
axis (HPA) [55]. ANS responses to stress are mediated
by the activation of the sympathetic nervous system
(SNS) and the following release of cathecolamines [56].
HPA responses to stress include hypothalamic produc-
tion of corticotrophin-releasing hormone (CRH) and
arginine vasopressin (AVP). These molecules activate the
secretion of pituitary hormones and adrenocorticotropic
hormones (ACTH), which induces the release of gluco-
corticoids from the adrenal cortex [55]. In this scenario,
glucocorticoids are the final effectors of the HPA axis,
which regulate CRH and ACTH secretion and limit the
duration of the total tissue exposure of the organism to
glucocorticoids [57].
In agreement with our findings connecting glucocorti-
coids with the invasiveness of DCIS, several studies have
linked glucocorticoids to the progression and malig-
nancy of breast cancer. In animal models, glucocorticoid
regulation following exposure to social isolation was as-
sociated with an increased mammary tumour burden
[28], while acute stressors were linked to abnormal
glucocorticoid regulation and increased mammary
tumour growth [58]. Pan et al. identified correlation
between the expression of GRs in estrogen receptor
(ER)− breast tumours with shorter relapse-free survival
[59]. In addition, women with metastatic breast cancer
frequently have flatter-than-normal diurnal cortisol pat-
terns and the degree of diurnal variation of glucocorti-
coids may predict earlier breast cancer mortality [60].
Glucocorticoids have also been linked to reduced immu-
nosurveillance, which is associated with the induction of
Fig. 6 Effects of glucocorticoids (GC) on ductal carcinoma in situ (DCIS) transition to invasive ductal carcinoma (IDC). Glucocorticoids promote
progression of DCIS to invasiveness by reducing laminin levels and inducing myoepithelial cell apoptosis in vitro and in vivo, effects that can be
partially blocked by the glucocorticoid receptor antagonist RU486
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tumour progression [61, 62]. These studies and our re-
sults suggest that a possible side effect of glucocorticoid
therapy would be a higher risk of evolution to invasive
breast cancer in patients who might have preneoplastic
lesions that have not been diagnosed.
After stress challenge or glucocorticoid treatment,
apoptotic myoepithelial cells were more frequent in pa-
tients with DCIS+IDC than in patients with DCIS, in
agreement with a study that described apoptosis in the
myoepithelial cell layer in comedo-type DCIS [13]. The
authors claimed that it was an early event associated
with the central necrosis of this type of DCIS, both in
MCF10DCIS xenografts and patient samples [13].
Samples from our patients with DCIS+IDC seemed to
display more malignant characteristics than those from
patients with DCIS. Since the apoptotic myoepithelial
cells are in the intact DCIS, this suggests that myoe-
pithelial cell apoptosis might be a prerequisite for
disruption of the myoepithelium and the consequent
invasion of the epithelial compartment into the stroma.
Conclusions
In conclusion, we found that chronic stress, through
sustained glucocorticoid treatment, plays a role in the
progression of DCIS to invasiveness, particularly by pro-
moting myoepithelial cell apoptosis in vitro and in vivo.
Myoepithelial cell apoptosis differentiates patients with
DCIS from those with DCIS+IDC, and might be a pre-
requisite for invasive features. Thus, the use of gluco-
corticoid inhibitors or other therapies that might
prevent myoepithelial cell apoptosis could potentially
interfere with and prevent the progression of DCIS to
invasiveness. In addition, the prevalence of apoptosis in
myoepithelial cells in DCIS samples might be used as a
prognostic factor for progression to IDC.
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µM by the Annexin V method and measured by flow cytometry. All
experiments were carried out in triplicate. Statistical analysis was made
using ANOVA followed by Dunn’s multiple test. c and d. Influence of
corticosterone treatment on 3D growth of primary epithelial and myoe-
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as nuclei counterstaining. Scale bar=50 µm. c Bottom part. Quantification
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hoechst to stain the nuclei. Arrows indicated rupture points of the acini
showed. F. Morphometric quantification of disrupted acini and acinar
fusion and intensity of laminin determined by integrated density param-
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out in triplicate. Statistical analysis was made using the Mann-Whitney
test. (PPTX 3174 kb)
Additional file 7: Figure S4. Representative immunofluorescence
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Hoechst in blue, p63 in red and laminin in green. b Merge of p63 and
laminin double immunofluorescence images and zoom in showing an
acini detail. Scale bar=20 µm. (PPT 4617 kb)
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